Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveSystemic therapies for pancreatic cancer--the role of pharmacogeneticsGenetic factors affecting patient responses to pancreatic cancer treatmentFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerGene expression analysis for predicting gemcitabine resistance in human cholangiocarcinomaDNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cellsAlgorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacyThe increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.Hypoxia-induced deoxycytidine kinase expression contributes to apoptosis in chronic lung disease.dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.Gemcitabine for the treatment of advanced nonsmall cell lung cancerGene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Patient-derived xenograft models: an emerging platform for translational cancer researchGemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.PharmGKB summary: gemcitabine pathwayGenexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinomaClinical pharmacology and pharmacogenetics of gemcitabine.Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancerMechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell linesNoninvasive prediction of tumor responses to gemcitabine using positron emission tomographyTreatment of pancreatic cancer: what can we really predict today?Post-transcriptional controls by ribonucleoprotein complexes in the acquisition of drug resistance.The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting.dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational StudyGemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.Drug metabolism and pancreatic cancer.Clinicopathological significance of deoxycytidine kinase expression in esophageal squamous cell carcinoma.HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.Challenges of drug resistance in the management of pancreatic cancer.HuR's role in gemcitabine efficacy: an exception or opportunity?Genomics and pharmacogenomics of pancreatic adenocarcinoma.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.
P2860
Q26752368-92E6DA15-0C98-455F-97BA-4F30F8A3744CQ27021716-722A8DBB-A06F-4B49-BE99-D8B128E8CF33Q28075293-34C163FF-374B-48D8-A49B-7D871CCFF1BEQ28075540-B9BBBE47-51A4-4080-9A99-4A3880876EEFQ28308112-13C68E23-4223-45F8-8F02-9267D947750DQ28481440-472DAA4C-E740-42F2-B6D8-D7AFC7B7BB3CQ28484288-5BC60083-FFDA-493D-9C69-5F5DEFEA02C8Q33591937-937EA62F-51EB-4A43-9139-55CEC965E9ADQ33713383-D6DDAE90-DD4D-4A6D-8F11-B019C00A7646Q33727842-7CE9F5AA-72D6-4E7B-B089-C4712A9CB733Q33915997-5BBCC83B-1E05-4922-A5CF-9F9002D02ECDQ34177223-BA54362E-1D27-4208-9D45-25BB862528B8Q34205518-C7D163A3-BAE5-467C-B69E-E327CCBEB2A8Q34254837-BAC08BD0-0F7B-4567-BA2E-2AE46D87AEC1Q34260205-F0B18F1C-C31A-4A6A-8688-A0A7BD392F4EQ34435450-879B5DDF-51B5-44CA-A26D-539C8B1133BFQ34625514-C76D3D9B-B015-4AF6-9C8E-9574D8D826F3Q34985979-D4A429EB-C683-4BFB-833B-CA5E1F7CB535Q35671422-57E82225-7E36-4613-923D-6700E9F0B677Q36201693-E43CC112-182F-4F1D-9426-745AD86818D8Q36610851-A884BB2B-037A-4E3C-9DCD-9255901E70B2Q36859193-74061ED3-250B-40F9-B169-E13983633C89Q37066258-4B52A9DC-ED7A-47EE-A4D3-55C78D7EA57FQ37085729-85B22873-A039-460A-A679-2331AC97FB1DQ37129815-223D3564-E3D3-44EB-9FE2-CC7FCCD14979Q37139289-A877D16F-3E79-44FB-9EFA-36D3379751DEQ37156381-737A74C9-CCA2-4B87-8E8E-412ABF91C376Q37207004-EF3F6814-1433-4A71-833D-F30E6649583EQ37249378-6DE36812-F1F7-4F6A-94E2-177A8AC624ADQ37253577-9261BE95-DA0A-472C-98AD-94D99B641649Q37268613-0CE0683A-DF66-450A-9397-07D0250957C4Q37347966-6E93A01C-69A4-4143-B336-5FD65DD1347EQ37542844-D503B23B-AF75-4814-A5FB-EF3D38608BE4Q37559699-3B98D794-971B-45AA-AF95-F9B4D74FBA96Q37614579-8166F478-8961-4B7E-BEBE-F393A97769CCQ37799830-B5A0BBC5-FBE2-4D70-A743-A7C5C8F77515Q37940426-FF165E26-2082-4CCB-8E67-D9BDC88167BDQ37970279-4A35C17B-160E-49B0-AA24-7694E82B40B2Q37994505-F50CE7A6-1164-4958-A7C8-F7335025B347Q38075827-6CF57F8B-3472-4CAD-9CBE-93C1408BA542
P2860
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Immunohistochemical and geneti ...... tabine resistance and survival
@en
type
label
Immunohistochemical and geneti ...... tabine resistance and survival
@en
prefLabel
Immunohistochemical and geneti ...... tabine resistance and survival
@en
P2093
P2860
P1476
Immunohistochemical and geneti ...... tabine resistance and survival
@en
P2093
Alison Klein
Belen Rubio-Viqueira
Charles J Yeo
Daniel Laheru
Francesca Ricci
Manuel Hidalgo
Piotr Kulesza
Valeria Sebastiani
P2860
P304
P356
10.1158/1078-0432.CCR-05-2655
P407
P577
2006-04-01T00:00:00Z